Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 71, Issue 11, Pages 3008-3019
Publisher
Oxford University Press (OUP)
Online
2016-08-06
DOI
10.1093/jac/dkw298
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model
- (2015) Seyedmojtaba Seyedmousavi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus
- (2015) Zaid Al-Nakeeb et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Isavuconazole in a DynamicIn VitroModel of Invasive Pulmonary Aspergillosis
- (2015) Helen Box et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits
- (2015) Ruta Petraitiene et al. CLINICAL INFECTIOUS DISEASES
- Tissue Penetration of Antifungal Agents
- (2014) T. Felton et al. CLINICAL MICROBIOLOGY REVIEWS
- Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days
- (2014) J. Livermore et al. mBio
- Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy andIn VitroSusceptibility Breakpoints
- (2013) Ajay Sudan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Isavuconazole (BAL4815) Pharmacodynamic Target Determination in anIn VivoMurine Model of Invasive Pulmonary Aspergillosis against Wild-Type andcyp51Mutant Isolates of Aspergillus fumigatus
- (2013) Alexander J. Lepak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- EUCAST Technical Note on Voriconazole and Aspergillus spp.
- (2013) W.W. Hope et al. CLINICAL MICROBIOLOGY AND INFECTION
- Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections
- (2013) Jodi Lestner et al. Expert Opinion on Drug Metabolism & Toxicology
- Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients
- (2013) Lucy O'Connor et al. JOURNAL OF INFECTIOUS DISEASES
- Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental Candida Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection
- (2012) J. L. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Interaction of Voriconazole and Anidulafungin against Triazole-Resistant Aspergillus fumigatus
- (2012) S. Seyedmousavi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Posaconazole Pharmacodynamic Target Determination against Wild-Type andCyp51Mutant Isolates of Aspergillus fumigatus in anIn VivoModel of Invasive Pulmonary Aspergillosis
- (2012) Alexander J. Lepak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Anidulafungin against Clinical Aspergillus fumigatus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis
- (2012) Seyedmojtaba Seyedmousavi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- DifferentialIn VivoActivities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and withoutFKSResistance Mutations
- (2012) Maiken Cavling Arendrup et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)*
- (2012) Maiken C. Arendrup et al. CLINICAL MICROBIOLOGY AND INFECTION
- Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints
- (2012) Adam R. Jeans et al. JOURNAL OF INFECTIOUS DISEASES
- Pharmacodynamic Effects of Simulated Standard Doses of Antifungal Drugs against Aspergillus Species in a NewIn VitroPharmacokinetic/Pharmacodynamic Model
- (2011) Joseph Meletiadis et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
- (2011) Nathan P. Wiederhold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin
- (2011) J. L. Slater et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Echinocandins against Candida glabrata: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts
- (2011) Susan J. Howard et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients
- (2011) Peter F. Troke et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Anidulafungin for Neonatal Hematogenous Candida Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach
- (2011) Peter A. Warn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy
- (2011) Susan J. Howard et al. JOURNAL OF INFECTIOUS DISEASES
- The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1->3)- -D-Glucan, and Consequences of Delayed Antifungal Therapy
- (2010) W. W. Hope et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Therapy for fungal diseases: opportunities and priorities
- (2010) David W. Denning et al. TRENDS IN MICROBIOLOGY
- Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene
- (2009) E. Mavridou et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside
- (2009) W.W. Hope et al. CLINICAL MICROBIOLOGY AND INFECTION
- In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model
- (2008) D. R. Andes et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- (1→3)-β-D-Glucan in Cereobrospinal Fluid is a Surrogate Marker for Detection and Therapeutic Response of Hematogenous Candida Meningoencephalitis
- (2008) Ruta Petraitiene et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- The Pharmacokinetics and Pharmacodynamics of Micafungin in Experimental HematogenousCandidaMeningoencephalitis: Implications for Echinocandin Therapy in Neonates
- (2007) William W. Hope et al. JOURNAL OF INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search